Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
karyotype
leukemia
mutation
myelofibrosis
prognosis
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
21
08
2019
accepted:
15
10
2019
pubmed:
17
1
2020
medline:
15
12
2020
entrez:
17
1
2020
Statut:
ppublish
Résumé
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University of Florence, Italy), including 502 ET and 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 in ET and SRSF2 in PV) and myelofibrosis-free (U2AF1, SF3B1 in ET) survival; TP53 mutations predicted leukaemic transformation in ET; "adverse" mutations occurred in 51 (10%) ET and 8 (2%) PV patients. We confirmed the independent survival effect of adverse mutations [hazard ratio (HR) 2·4, 95% CI 1·6-3·5], age >60 years (6·6, 4·6-9·7), male sex (1·8, 1·3-2·4) and leukocytosis ≥11 × 10
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-302Subventions
Organisme : Mayo Clinic
Pays : International
Organisme : Henry J. Predolin foundation
Pays : International
Organisme : University of Florence
Pays : International
Organisme : Associazione Italiana per la Ricerca sul Cancro
Pays : International
Organisme : MYeloid NEoplasms Research Venture AIRC
ID : 21267
Pays : International
Organisme : Progetto Ministero della Salute
ID : GR-2011-02352109
Pays : International
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., le Beau, M.M., Bloomfield, C.D., Cazzola, M. & Vardiman, J.W. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-405.
Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., D'Amore, E.S., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Antonioli, E., Carrai, V., Gisslinger, H., Buxhofer-Ausch, V., Mullauer, L., Carobbio, A., Gianatti, A., Gangat, N., Hanson, C.A. & Tefferi, A. (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. Journal of Clinical Oncology, 29, 3179-3184.
Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A.; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437-438.
Barraco, D., Cerquozzi, S., Hanson, C.A., Ketterling, R.P., Pardanani, A.D., Gangat, N. & Tefferi, A. (2017) Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. British Journal of Haematology, 182, 437-440.
Cerquozzi, S. & Tefferi, A. (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer Journal, 5, e366.
Elala, Y.C., Lasho, T.L., Gangat, N., Finke, C., Barraco, D., Haider, M., Abou Hussein, A.K., Hanson, C.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2016) Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American Journal of Hematology, 91, 503-506.
Gangat, N., Tefferi, A., Thanarajasingam, G., Patnaik, M., Schwager, S., Ketterling, R. & Wolanskyj, A.P. (2009) Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. European Journal of Haematology, 83, 17-21.
Grinfeld, J., Nangalia, J., Baxter, E.J., Wedge, D.C., Angelopoulos, N., Cantrill, R., Godfrey, A.L., Papaemmanuil, E., Gundem, G., Maclean, C., Cook, J., O'Neil, L., O'Meara, S., Teague, J.W., Butler, A.P., Massie, C.E., Williams, N., Nice, F.L., Andersen, C.L., Hasselbalch, H.C., Guglielmelli, P., McMullin, M.F., Vannucchi, A.M., Harrison, C.N., Gerstung, M., Green, A.R. & Campbell, P.J. (2018) Classification and personalized prognosis in myeloproliferative neoplasms. New England Journal of Medicine, 379, 1416-1430.
Guglielmelli, P., Gangat, N., Coltro, G., Lasho, T.L., Loscocco, G.G., Finke, C., Sordi, B., Mudireddy, M., Rotunno, G., Szuber, N., Pacilli, A., Vallapureddy, R.R., Nicolosi, M., Penna, D., Hanson, C.A., Ketterling, R.P., Pardanani, A., Vannucchi, A.M. & Tefferi, A. (2018a) Mutations and Thrombosis in essential thrombocythemia and polycythemia vera: Mayo-Careggi Alliance Study. Blood, 132, 3040.
Guglielmelli, P., Lasho, T.L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., Hanson, C.A., Mannelli, F., Ketterling, R.P., Gangat, N., Rambaldi, A., Passamonti, F., Barosi, G., Barbui, T., Cazzola, M., Vannucchi, A.M. & Tefferi, A. (2018b) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. Journal of Clinical Oncology, 36, 310-318.
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Ades, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N.C., Preudhomme, C., Bernard, O.A., Fontenay, M., Vainchenker, W., Schnittger, S., Birnbaum, D., Droin, N. & Solary, E. (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 2428-2436.
James, C., Ugo, V., le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
Kennedy, J.A. & Ebert, B.L. (2017) Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. Journal of Clinical Oncology, 35, 968-974.
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R. & Skoda, R.C. (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood, 123, 2220-2228.
Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J.J., Cervantes, F., Devos, T., Palandri, F., de Stefano, V., Ruggeri, M., Silver, R.T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A.M. & Passamonti, F. (2018) Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 103, e392-e394.
Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
Passamonti, F., Thiele, J., Girodon, F., Rumi, E., Carobbio, A., Gisslinger, H., Kvasnicka, H.M., Ruggeri, M., Randi, M.L., Gangat, N., Vannucchi, A.M., Gianatti, A., Gisslinger, B., Mullauer, L., Rodeghiero, F., D'Amore, E.S., Bertozzi, I., Hanson, C.A., Boveri, E., Marino, F., Maffioli, M., Caramazza, D., Antonioli, E., Carrai, V., Buxhofer-Ausch, V., Pascutto, C., Cazzola, M., Barbui, T. & Tefferi, A. (2012) A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 120, 1197-201.
Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G.A., Yelensky, R., Hricik, T., McKenney, A.S., Chiosis, G., Chung, Y.R., Pandey, S., van den Brink, M.R., Armstrong, S.A., Dogan, A., Intlekofer, A., Manshouri, T., Park, C.Y., Verstovsek, S., Rapaport, F., Stephens, P.J., Miller, V.A. & Levine, R.L. (2014) Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 111, E5401-E5410.
Senin, A., Fernandez-Rodriguez, C., Bellosillo, B., Camacho, L., Longaron, R., Angona, A., Besses, C. & Alvarez-Larran, A. (2018) Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Annals of Hematology, 97, 443-451.
Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (eds) (2009). ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Basel, Karger.
Tang, G., Hidalgo Lopez, J.E., Wang, S.A., Hu, S.,Ma, J., Pierce, S., Zuo, W., Carballo-Zarate, A.A., Yin, C.C., Tang, Z., Li, S., Medeiros, L.J., Verstovsek, S. & Bueso-Ramos, C.E. (2017) Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica, 102, 1511-1518.
Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A.M., Rodeghiero, F., Randi, M.L., Vaidya, R., Cazzola, M., Rambaldi, A., Gisslinger, B., Pieri, L., Ruggeri, M., Bertozzi, I., Sulai, N.H., Casetti, I., Carobbio, A., Jeryczynski, G., Larson, D.R., Mullauer, L., Pardanani, A., Thiele, J., Passamonti, F. & Barbui, T. (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 27, 1874-1881.
Tefferi, A., Guglielmelli, P., Larson, D.R., Finke, C., Wassie, E.A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A.A., Lasho, T.L., Ketterling, R.P., Hanson, C.A., Rambaldi, A., Finazzi, G., Thiele, J., Barbui, T., Pardanani, A. & Vannucchi, A.M. (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 124, 2507-2513.
Tefferi, A., Lasho, T.L., Finke, C.M., Elala, Y., Hanson, C.A., Ketterling, R.P., Gangat, N. & Pardanani, A. (2016a) Targeted deep sequencing in primary myelofibrosis. Blood Advances, 1, 105-111.
Tefferi, A., Lasho, T.L., Guglielmelli, P., Finke, C.M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C.A., Pancrazzi, A., Ketterling, R.P., Mannarelli, C., Barraco, D., Fanelli, T., Pardanani, A., Gangat, N. & Vannucchi, A.M. (2016b) Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 1, 21-30.
Tefferi, A., Finke, C.M., Lasho, T.L., Hanson, C.A., Ketterling, R.P., Gangat, N. & Pardanani, A. (2018a) U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia, 32, 2274-2278.
Tefferi, A., Gangat, N., Mudireddy, M., Lasho, T.L., Finke, C., Begna, K.H., Elliott, M.A., Al-Kali, A., Litzow, M.R., Hook, C.C., Wolanskyj, A.P., Hogan, W.J., Patnaik, M.M., Pardanani, A., Zblewski, D.L., He, R., Viswanatha, D., Hanson, C.A., Ketterling, R.P., Tang, J.L., Chou, W.C., Lin, C.C., Tsai, C.H., Tien, H.F. & Hou, H.A. (2018b) Mayo alliance prognostic model for myelodysplastic syndromes: integration of genetic and clinical information. Mayo Clinic Proceedings, 93, 1363-1374.
Tefferi, A., Guglielmelli, P., Lasho, T.L., Gangat, N., Ketterling, R.P., Pardanani, A. & Vannucchi, A.M. (2018c) MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. Journal of Clinical Oncology, 36, 1769-1770.
Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Finke, C.M., Lasho, T.L., Hanson, C.A., Ketterling, R.P., Begna, K.H., Naseema, G., Pardanani, A. & Vannucchi, A.M. (2018d) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 32, 1631-1642.
Tefferi, A., Nicolosi, M., Mudireddy, M., Lasho, T.L., Gangat, N., Begna, K.H., Hanson, C.A., Ketterling, R.P. & Pardanani, A. (2018e) Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 32, 1189-1199.
Vannucchi, A.M., Lasho, T.L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., Ketterling, R.P., Rotunno, G., Knudson, R.A., Susini, M.C., Laborde, R.R., Spolverini, A., Pancrazzi, A., Pieri, L., Manfredini, R., Tagliafico, E., Zini, R., Jones, A., Zoi, K., Reiter, A., Duncombe, A., Pietra, D., Rumi, E., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C. & Tefferi, A. (2013) Mutations and prognosis in primary myelofibrosis. Leukemia, 27, 1861-1869.